CDA | Evidence Driven
CDA | Evidence Driven

Proleukin for In-transit Melanoma - Details

Details

Files
Generic Name:
Aldesleukin (IL-2)
Project Status:
Complete
Therapeutic Area:
In-transit Melanoma
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Proleukin
Project Line:
Reimbursement Review
Project Number:
PC0051-000
Performance Metric:
N/A — Predated performance metrics
Strength:
22 million IU/vial
Tumour Type:
Skin and Melanoma
Indications:
In-transit Melanoma
Funding Request:
Administered intra-lesionally, for the treatment of in-transit metastasis from melanoma in patients who have failed or are not candidates for surgery or other treatments
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Cancer Care Ontario Melanoma Disease Site Group
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma - Final pERC Recommendation Final Recommendation June 22, 2015 View PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma – Final Clinical Guidance Report Guidance Reports June 22, 2015 View PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma – Final Economic Guidance Report Guidance Reports June 22, 2015 View PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma – Initial Recommendation Initial Recommendation June 4, 2015 View PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma - PAG Feedback on Initial Recommendation Feedback June 22, 2015 View PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma – Submitter Feedback on Initial recommendation Feedback June 22, 2015 View PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma – Patient Advocacy Group (MNC) Feedback on Initial Recommendation Feedback June 22, 2015 View PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma – Patient Advocacy Group (MNC) COI COI June 22, 2015 View PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma – Patient Advocacy Group (SYSF) COI COI June 22, 2015 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : July 31, 2015